Grace Therapeutics (GRCE) Expected to Announce Earnings on Thursday

Grace Therapeutics (NASDAQ:GRCE) is projected to announce its Q3 2026 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Wednesday, February 11, 2026 at 6:00 PM ET.

Grace Therapeutics (NASDAQ:GRCE) last released its earnings results on Thursday, November 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). On average, analysts expect Grace Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Grace Therapeutics Stock Down 0.8%

Shares of GRCE opened at $3.68 on Thursday. Grace Therapeutics has a 52 week low of $1.75 and a 52 week high of $3.94. The stock has a market cap of $56.93 million, a P/E ratio of -5.94 and a beta of 0.76. The business’s 50 day moving average price is $3.49 and its 200-day moving average price is $3.24.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Grace Therapeutics stock. SeaCrest Wealth Management LLC acquired a new stake in shares of Grace Therapeutics, Inc. (NASDAQ:GRCE) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,000 shares of the company’s stock, valued at approximately $42,000. SeaCrest Wealth Management LLC owned 0.10% of Grace Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 6.08% of the company’s stock.

Analyst Ratings Changes

GRCE has been the topic of a number of recent research reports. Wall Street Zen raised Grace Therapeutics to a “hold” rating in a research note on Friday, January 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $12.00.

About Grace Therapeutics

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.